MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies for inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer on May 27, 2025. The leadership change marks a strategic shift toward maximizing the global commercial potential of the company's flagship product Wynzora Cream and its proprietary PAD Technology formulation platform.
New Leadership Brings Extensive Commercial Experience
Ahlgreen brings a comprehensive background in pharmaceutical commercial leadership spanning global, regional and local product launches across Europe, the US and Japan. Her experience includes successful cross-functional team leadership and business development initiatives at major pharmaceutical companies.
At Novo Nordisk, Ahlgreen played key roles in several high-impact product launches, including Ozempic, Rybelsus and the global cardiovascular indication launch for GLP-1 therapies. Most recently, at Swiss biotech Micreos Pharmaceuticals AG, she built commercial and business development infrastructure focused on dermatology, establishing strategic partnerships across both pharmaceutical and over-the-counter markets.
"MC2 Therapeutics has developed world-class innovation in topical therapies with a unique commitment to patient adherence and uncompromised efficacy," said Ahlgreen. "I'm honored to lead the next phase of the company's growth, focused on realizing the full global commercial potential of Wynzora Cream for plaque psoriasis, while exploring new opportunities through our proprietary PAD Technology formulation platform with selected partners."
Wynzora Cream's Clinical Profile and Market Performance
Wynzora Cream represents a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis in adults. The therapy demonstrates a broad mode of action by targeting keratinocyte proliferation and differentiation while inhibiting expression of pro-inflammatory cytokines including IL-23, IL-17A/F and TNF-α.
The treatment is uniquely enabled by MC2 Therapeutics' PAD Technology, an innovative formulation and delivery system that allows for an effective, convenient-to-use aqueous formulation. This proprietary technology has been shown to significantly improve patient satisfaction and may support better treatment adherence, which represents an essential factor in managing chronic dermatologic conditions.
Wynzora Cream received FDA approval in the United States on July 20, 2020, and gained approval in the first European country on July 9, 2021. The product has demonstrated strong clinical value and achieved successful uptake in key European markets, with potential for strengthened market leadership.
Strategic Focus on Global Expansion
The leadership transition reflects MC2 Therapeutics' planned strategic evolution aligned with commercial expansion objectives. Under renewed focus and disciplined execution, the company will intensify efforts to expand Wynzora Cream's global reach.
The company's flagship drug is currently partnered with leading pharmaceutical companies specialized in dermatology across more than 40 countries on four continents. MC2 Therapeutics has established commercial manufacturing relationships with three contract manufacturing organizations across the EU and US to support global growth initiatives.
Leadership Succession
The appointment follows the tenure of Jesper J. Lange, who served as CEO since the company's inception. Under Lange's entrepreneurial leadership, MC2 Therapeutics developed Wynzora Cream, formed strategic alliances with key partners across four continents, and established the commercial manufacturing infrastructure necessary for global expansion.
MC2 Therapeutics, based in Hørsholm, Denmark and Guildford, United Kingdom, remains a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative therapies and support systems.
